발기부전 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Erectile Dysfunction Drugs Market size is expected to reach USD 9.04 Billion in 2034 from USD 4.11 Billion (2025) growing at a CAGR of 9.14% during 2026-2034.

The global erectile dysfunction drugs market is growing steadily due to increasing prevalence of lifestyle-related disorders. Rising awareness about men's health issues is encouraging treatment adoption worldwide. The growing aging male population significantly contributes to demand growth. Availability of generic alternatives has improved affordability and accessibility. These factors collectively drive consistent market expansion.

Key drivers include rising cases of diabetes, hypertension, and cardiovascular diseases. Stressful lifestyles and sedentary habits are increasing the incidence of erectile dysfunction. Online pharmacies and telehealth platforms are improving drug accessibility. Pharmaceutical companies are investing in improved formulations with fewer side effects. Expanding healthcare access in developing countries is further supporting demand.

Future prospects remain favorable with ongoing research into advanced treatment options. Development of longer-lasting and more effective medications offers growth opportunities. Increased social acceptance of treatment will support higher adoption rates. Emerging markets present significant untapped potential for manufacturers. Continuous innovation in drug delivery systems will shape future market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Sildenafil
• Tadalafil
• Vardenafil
• Avanafil
• Others

By Mode of Administration

• Oral Tablets
• Injectables
• Topical Medications

By End User

• Hospitals
• Clinics
• Homecare

COMPANIES PROFILED

• Teva Pharmaceutical Industries Ltd, SK Chemicals Co Ltd, Cristalia Produtos Qumicos Farmacuticos Ltd, Futura Medical plc, GlaxoSmithKline PLC, Petros Pharmaceuticals, Lupin Limited, Glenmark Pharmaceuticals Limited, Cipla Ltd, Endo International plc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Sildenafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tadalafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vardenafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Avanafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY MODE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mode Of Administration
• 5.2. Oral Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Mode Of Administration
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Mode Of Administration
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Mode Of Administration
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Mode Of Administration
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Mode Of Administration
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ERECTILE DYSFUNCTION DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Teva Pharmaceutical Industries Ltd
  • 9.2.2 S.K. Chemicals Co. Ltd
  • 9.2.3 Cristalia Produtos QuAfA-Micos FarmacAfAªUticos Ltd
  • 9.2.4 Futura Medical Plc
  • 9.2.5 GlaxoSmithKline PLC
  • 9.2.6 Petros Pharmaceuticals
  • 9.2.7 Lupin Limited
  • 9.2.8 Glenmark Pharmaceuticals Limited
  • 9.2.9 Cipla Ltd
  • 9.2.10 Endo International Plc